201 related articles for article (PubMed ID: 31700186)
1. Chromatin regulators mediate anthracycline sensitivity in breast cancer.
Seoane JA; Kirkland JG; Caswell-Jin JL; Crabtree GR; Curtis C
Nat Med; 2019 Nov; 25(11):1721-1727. PubMed ID: 31700186
[TBL] [Abstract][Full Text] [Related]
2. Dual functions of the homeoprotein DLX4 in modulating responsiveness of tumor cells to topoisomerase II-targeting drugs.
Trinh BQ; Ko SY; Barengo N; Lin SY; Naora H
Cancer Res; 2013 Jan; 73(2):1000-10. PubMed ID: 23222298
[TBL] [Abstract][Full Text] [Related]
3. Spatial Chromosome Folding and Active Transcription Drive DNA Fragility and Formation of Oncogenic MLL Translocations.
Gothe HJ; Bouwman BAM; Gusmao EG; Piccinno R; Petrosino G; Sayols S; Drechsel O; Minneker V; Josipovic N; Mizi A; Nielsen CF; Wagner EM; Takeda S; Sasanuma H; Hudson DF; Kindler T; Baranello L; Papantonis A; Crosetto N; Roukos V
Mol Cell; 2019 Jul; 75(2):267-283.e12. PubMed ID: 31202576
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of histone H2A and H2B pathways is associated with anthracycline sensitivity in breast cancer.
Braunstein M; Liao L; Lyttle N; Lobo N; Taylor KJ; Krzyzanowski PM; Kalatskaya I; Yao CQ; Stein LD; Boutros PC; Twelves CJ; Marcellus R; Bartlett JM; Spears M
Breast Cancer Res; 2016 Feb; 18(1):16. PubMed ID: 26852132
[TBL] [Abstract][Full Text] [Related]
5. Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer.
Cardoso F; Durbecq V; Larsimont D; Paesmans M; Leroy JY; Rouas G; Sotiriou C; Renard N; Richard V; Piccart MJ; Di Leo A
Int J Oncol; 2004 Jan; 24(1):201-9. PubMed ID: 14654958
[TBL] [Abstract][Full Text] [Related]
6. Topoisomerase II-alfa gene as a predictive marker of response to anthracyclines in breast cancer.
Almeida D; Gerhard R; Leitão D; Davilla C; Damasceno M; Schmitt F
Pathol Res Pract; 2014 Oct; 210(10):675-9. PubMed ID: 25042383
[TBL] [Abstract][Full Text] [Related]
7. Topoisomerase IIalpha gene amplification and response to anthracycline-containing adjuvant chemotherapy in breast cancer.
Buzdar AU
J Clin Oncol; 2006 Jun; 24(16):2409-11. PubMed ID: 16682721
[No Abstract] [Full Text] [Related]
8. Topoisomerase II alpha and microtubule-associated protein-tau as a predictive marker in axillary lymph node positive breast cancer.
Won HS; Lee KE; Sung SH; Choi MY; Jo JY; Nam EM; Mun YC; Seong CM; Lee SN
Tumori; 2014; 100(1):80-6. PubMed ID: 24675496
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase II α Gene alteration in Triple Negative Breast Cancer and Its Predictive Role for Anthracycline-Based Chemotherapy (Egyptian NCI Patients).
Eltohamy MI; Badawy OM; El kinaai N; Loay I; Nassar HR; Allam RM; Sakr MA
Asian Pac J Cancer Prev; 2018 Dec; 19(12):3581-3589. PubMed ID: 30583686
[TBL] [Abstract][Full Text] [Related]
10. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.
Di Leo A; Desmedt C; Bartlett JM; Piette F; Ejlertsen B; Pritchard KI; Larsimont D; Poole C; Isola J; Earl H; Mouridsen H; O'Malley FP; Cardoso F; Tanner M; Munro A; Twelves CJ; Sotiriou C; Shepherd L; Cameron D; Piccart MJ; Buyse M;
Lancet Oncol; 2011 Nov; 12(12):1134-42. PubMed ID: 21917518
[TBL] [Abstract][Full Text] [Related]
11. Studies on Non-synonymous Polymorphisms Altering Human DNA Topoisomerase II-Alpha Interaction with Amsacrine and Mitoxantrone: An
Farsani FM; Ganjalikhany MR; Vallian S
Curr Cancer Drug Targets; 2017; 17(7):657-668. PubMed ID: 27834128
[TBL] [Abstract][Full Text] [Related]
12. Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning?
Di Leo A; Isola J
Clin Breast Cancer; 2003 Aug; 4(3):179-86. PubMed ID: 14499010
[TBL] [Abstract][Full Text] [Related]
13. The role of topoisomerase IIα in predicting sensitivity to anthracyclines in breast cancer patients: a meta-analysis of published literatures.
Du Y; Zhou Q; Yin W; Zhou L; Di G; Shen Z; Shao Z; Lu J
Breast Cancer Res Treat; 2011 Oct; 129(3):839-48. PubMed ID: 21809115
[TBL] [Abstract][Full Text] [Related]
14. Reflections on the development of resistance during therapy for advanced breast cancer. Implications of high levels of activity of docetaxel in anthracycline-resistant breast cancer patients.
Ravdin PM
Eur J Cancer; 1997 Aug; 33 Suppl 7():S7-10. PubMed ID: 9486096
[TBL] [Abstract][Full Text] [Related]
15. Multifactorial approach to predicting resistance to anthracyclines.
Desmedt C; Di Leo A; de Azambuja E; Larsimont D; Haibe-Kains B; Selleslags J; Delaloge S; Duhem C; Kains JP; Carly B; Maerevoet M; Vindevoghel A; Rouas G; Lallemand F; Durbecq V; Cardoso F; Salgado R; Rovere R; Bontempi G; Michiels S; Buyse M; Nogaret JM; Qi Y; Symmans F; Pusztai L; D'Hondt V; Piccart-Gebhart M; Sotiriou C
J Clin Oncol; 2011 Apr; 29(12):1578-86. PubMed ID: 21422418
[TBL] [Abstract][Full Text] [Related]
16. Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment.
Bouchalova K; Cizkova M; Cwiertka K; Trojanec R; Hajduch M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar; 153(1):13-7. PubMed ID: 19365520
[TBL] [Abstract][Full Text] [Related]
17. Alterations in the TOP2A and HER2 genes: association with adjuvant anthracycline sensitivity in human breast cancers.
Slamon DJ; Press MF
J Natl Cancer Inst; 2009 May; 101(9):615-8. PubMed ID: 19401550
[No Abstract] [Full Text] [Related]
18. Long non-coding RNA profiling links subgroup classification of endometrioid endometrial carcinomas with trithorax and polycomb complex aberrations.
Jiang Y; Malouf GG; Zhang J; Zheng X; Chen Y; Thompson EJ; Weinstein JN; Yuan Y; Spano JP; Broaddus R; Tannir NM; Khayat D; Lu KH; Su X
Oncotarget; 2015 Nov; 6(37):39865-76. PubMed ID: 26431491
[TBL] [Abstract][Full Text] [Related]
19. DNA-PKcs-mediated transcriptional regulation of TOP2B drives chemoresistance in acute myeloid leukemia.
Mishra SV; Banerjee A; Sarkar D; Thangarathnam V; Bagal B; Hasan SK; Dutt S
J Cell Sci; 2024 Feb; 137(3):. PubMed ID: 38240344
[TBL] [Abstract][Full Text] [Related]
20. Alterations in estrogen signalling pathways upon acquisition of anthracycline resistance in breast tumor cells.
Chewchuk S; Guo B; Parissenti AM
PLoS One; 2017; 12(2):e0172244. PubMed ID: 28196134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
